FERRISELTZ
LOE ApproachingNDAORALFOR SOLUTION
Approved
Oct 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERRISELTZ is an oral solution approved in 1997 by Otsuka Pharmaceutical for an undisclosed indication. The specific mechanism of action and therapeutic class remain unknown from available data.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%) signals potential team right-sizing and focus shift to managed care/generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, FERRISELTZ represents a consolidation/transition career opportunity rather than growth. Professionals joining this team should expect focus on margin protection, payer negotiations, and generic transition strategies rather than market expansion.
Brand ManagerProduct Manager
Worked on FERRISELTZ at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.